{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:49:38Z","timestamp":1791218978687,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gonadotropin\u2010releasing hormone agonists and antagonists provide androgen\u2010deprivation therapy for prostate cancer. Unlike agonists, gonadotropin\u2010releasing hormone antagonists have a direct mode of action to block pituitary gonadotropin\u2010releasing hormone receptors. There are two licensed gonadotropin\u2010releasing hormone antagonists, degarelix and abarelix. Of these, degarelix is the more extensively studied and has been documented to be more effective than the well\u2010established, first\u2010line agonist, leuprolide, in terms of substantially faster onset of castration, faster suppression of prostate\u2010specific antigen, no risk for testosterone surge or clinical flare, and improved prostate\u2010specific antigen progression\u2010free survival, suggesting a delay in castration resistance. Other than minor injection\u2010site reactions, degarelix is generally well tolerated, without systemic allergic reactions and with most adverse events consistent with androgen suppression or the underlying condition. In conclusion, degarelix provides a rational, first\u2010line androgen\u2010deprivation therapy suitable for the treatment of prostate cancer, with faster onset of castration than with agonists, and no testosterone surge. Furthermore, data suggest that degarelix improves disease control compared with leuprolide, and might delay the onset of castration\u2010resistant disease. In view of these clinical benefits and the lack of need for concomitant anti\u2010androgen treatment, gonadotropin\u2010releasing hormone antagonists might replace gonadotropin\u2010releasing hormone agonists as first\u2010line androgen\u2010deprivation therapy in the future.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2012.02997.x","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T18:59:41Z","timestamp":1331751581000},"page":"594-601","source":"Crossref","is-referenced-by-count":89,"title":["Gonadotropin\u2010releasing hormone: An update review of the antagonists versus agonists"],"prefix":"10.1111","volume":"19","author":[{"given":"Hein","family":"Van Poppel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.070"},{"issue":"3","key":"e_1_2_11_3_2","first-page":"S10","article-title":"Flare associated with LHRH\u2010agonist therapy","volume":"3","author":"Thompson IM","year":"2001","journal-title":"Rev. Urol."},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2005.08.004"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.129"},{"issue":"2","key":"e_1_2_11_6_2","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3747\/co.v17i0.718","article-title":"Current management of castrate\u2010resistant prostate cancer","volume":"17","author":"Hotte SJ","year":"2010","journal-title":"Curr. Oncol."},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.027"},{"key":"e_1_2_11_8_2","unstructured":"HeidenreichA BollaM JoniauSet\u2003al.2011.Guidelines on prostate cancer. [Cited 8 August 2011.] Available from URL:http:\/\/www.uroweb.org\/gls\/pdf\/08_Prostate_Cancer.pdf"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05798.x"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05946.x"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.4065\/82.2.243"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-10-0343"},{"key":"e_1_2_11_13_2","first-page":"885","volume-title":"Textbook of Medical Physiology","author":"Guyton AC","year":"1991"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00922743"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112326"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.10.2171"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.065"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.07.033"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.083"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01342-5"},{"issue":"5","key":"e_1_2_11_22_2","first-page":"78","article-title":"Comparison of abarelix depot (A\u2010D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open\u2010label, randomised, phase III study","volume":"39","author":"Selvaggi F","year":"2001","journal-title":"Eur. Urol."},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66353-7"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200204000-00021"},{"key":"e_1_2_11_25_2","unstructured":"Plenaxis Drug Information.2011. [Cited 8 August 2011]. Available from URL:http:\/\/www.rxlist.com\/plenaxis\u2010drug.htm#"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.04.048"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4246"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9810"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.11.029"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(10)60144-3"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000231476.84782.55"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000059584.47272.9d"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287211414457"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1145"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2008.36"},{"key":"e_1_2_11_36_2","unstructured":"US Food and Drug Administration.2010.GnRH agonists: label change \u2013 increased risk of diabetes and cardiovascular disease (update). [Cited 8 August 2011]. Available from URL:http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm230359.htm"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.012"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.07.035"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.2.6.677"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2008.09.003"},{"key":"e_1_2_11_41_2","unstructured":"WaknineY.2005.International approvals: plenaxis tostrex troxatyl. [Cited 8 August 2011]. Available from URL:http:\/\/www.medscape.com\/viewarticle\/513892"},{"key":"e_1_2_11_42_2","unstructured":"Specialty European Pharma.2011.Your partner in urology. [Cited 8 August 2011]. Available from URL:http:\/\/www.specialityeuropeanpharma.com"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.1.95"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03730.x"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08981.x"},{"key":"e_1_2_11_46_2","unstructured":"AndersonJ Al\u2010AliG WirthMet\u2003al.Improved relief of lower urinary tract symptoms (LUTS) with a gonadotrophin\u2010releasing hormone (GnRH) blocker compared with an agonist + antiandrogen (AA) in an open\u2010label randomised study (CS28). Abstract presented at the European Multidisciplinary Meeting on Urological Cancers Barcelona Spain 2011."}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2012.02997.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2012.02997.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:55:39Z","timestamp":1697345739000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2012.02997.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1442-2042.2012.02997.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2012.02997.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}